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A retrospective survey was conducted to characterize -lactamases in a collection of 43 ceftazidime-resistant
Pseudomonas aeruginosa isolates recovered from patients with bloodstream infections hospitalized at a Bra-
zilian teaching hospital between January and December 2005. Resistance rates for carbapenems, aminogly-
cosides, and quinolones were over 80%, with only colistin remaining active against all isolates. Pulsed-field gel
electrophoresis analysis identified seven different genotypes. AmpC overproduction was found to be the sole
-lactamase-mediated mechanism responsible for ceftazidime resistance in four isolates (9.3%). Nine isolates
(20.9%) produced an extended-spectrum -lactamase (ESBL), either GES-1 (n  7, 16.3%) or CTX-M-2 (n 
2, 4.6%). Carbapenemase activity was detected in 30 (70%) additional isolates. Among those isolates, two
isolates (4.6%) produced the ESBL GES-5, possessing the ability to hydrolyze imipenem; a single isolate (2.3%)
produced the metallo--lactamase (MBL) IMP-1; and 27 isolates produced the MBL SPM-1 (62.8%). None of
the isolates coproduced both ESBL and MBL. Insertion sequence elements ISCR4 and ISCR1 were associated
with blaSPM-1 and blaCTX-M-2 genes, respectively, whereas the blaGES-1 and blaGES-5 genes were part of class 1
integron structures. This study underlines the spread of MBL- and ESBL-producing P. aeruginosa isolates as
an important source of ceftazidime resistance in Brazil.
Pseudomonas aeruginosa is a leading cause of hospital-
acquired infections. Acquisition of -lactamases, such as class
A extended-spectrum -lactamases (ESBLs) and class B
metallo--lactamases (MBLs), by P. aeruginosa nosocomial
isolates is detrimental to antimicrobial therapy in hospitalized
patients (19).
The ESBLs reported for P. aeruginosa are SHV, TEM, PER,
VEB, BEL, GES, and, more recently, CTX-M types (1, 7, 8, 16,
20, 23, 29). The GES-type enzymes are unusual since point
amino acid changes in their active sites may extend their hy-
drolytic activity to carbapenems (31, 39, 40). ESBL production
in P. aeruginosa has been documented in Brazil (2, 5, 21), but
its prevalence remains unknown.
Five types of acquired MBLs have been identified in P.
aeruginosa: IMP, VIM, SPM, GIM, and AIM (41, 42). In Bra-
zil, IMP-, VIM-, and SPM-producing P. aeruginosa clinical
isolates have been identified (35). In addition, SPM producers
have been reported as endemic in Brazilian territory due to
dissemination of a single clone (10).
The aim of this study was to investigate the diversity and
frequency of both ESBL and MBL production and to charac-
terize the genetic support of those acquired -lactamase genes
in a collection of ceftazidime-resistant P. aeruginosa clinical
isolates from Brazil, taken as a model of a developing country.
MATERIALS AND METHODS
Bacterial strains. A total of 154 consecutive P. aeruginosa isolates were re-
covered from patients with bloodstream infections hospitalized at Hospital Sa˜o
Paulo between January and December 2005. A single isolate per patient was
retained for this study. Among those isolates, 43 (28%) were ceftazidime resis-
tant by the CLSI disk diffusion method (inhibition zone of 14 mm and MIC
of 32 g/ml) and thus were further characterized. Escherichia coli TOP10 was
used as a recipient strain in cloning experiments (23). Transformation experi-
ments were performed using both E. coli TOP10 and P. aeruginosa PAO1 as the
recipients.
Clinical data. Clinical data including age, comorbidities, unit of the hospital,
site of infection, therapeutic regimen, and final disposition (death or discharge)
have been collected for each patient.
Susceptibility testing and screening for AmpC overproducers and/or ESBL
production. Antibiotic susceptibility profiles of the 43 P. aeruginosa isolates were
determined by the agar dilution method according to the CLSI guidelines (3).
AmpC overproducers were identified by testing susceptibility to ceftazidime on
Mueller-Hinton plates supplemented with 250 g/ml cloxacillin (18, 33). Detec-
tion of ESBL production was carried out by a double disk synergy method testing
ceftazidime, aztreonam, and cefepime at a distance of 15 mm from ticarcillin-
clavulanic acid disks, on Mueller-Hinton plates supplemented or not with clox-
acillin-containing plates (28).
Screening for carbapenemase activity. Hydrolysis of imipenem was assessed by
UV spectrophotometry assays, as described previously (10, 11, 25). Briefly, 10 ml
of an overnight broth culture was harvested and then disrupted by sonication.
Whole-protein extracts were obtained after centrifugation. Hydrolytic activity of
20 l of the crude extract was determined against 100 M imipenem in 100 mM
phosphate buffer (pH 7.0), and measurements were carried out at a wavelength
of 297 nm.
PCR amplification for detection of ESBL and MBL genes; analysis of the
genetic environment and sequencing. Specific primers were used under standard
PCR conditions to detect ESBL- and MBL-encoding genes, namely, blaTEM,
blaSHV, blaCTX-M, blaGES, blaPER, blaVEB, blaBEL, blaKPC, blaIMP, blaVIM,
blaSPM, blaGIM, and blaAIM (7, 12, 15, 16, 17, 20, 23, 26, 29, 30, 38, 42). The
genetic environment of blaIMP was determined by PCR using the previously
published specific primers to anneal at the 5 and 3 conserved sequences (CSs)
of class 1 integrons, followed by sequencing (24). The genetic environment of
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blaCTX-M-2 was determined by PCR and further sequencing using specific prim-
ers for the insertion sequence ISCR1 located upstream and for the qacE1 and
sul1 tandem gene (17). The genetic context of blaSPM-1 was determined by using
primers hybridizing with ISCR4, as described previously (27). For direct DNA
sequencing, PCR products were purified using PCR purification columns
(Qiagen, Courtaboeuf, France). Sequencing reactions were performed using
specific primers and an automated ABI 337 sequencer (Applied Biosystems,
Foster City, CA). The nucleotide and deduced protein sequences were analyzed
with software available over the Internet at the National Center for Biotechnol-
ogy Information website (http://www.ncbi.nlm.nih.gov).
PFGE analysis. Genetic relatedness among the ceftazidime-resistant P. aerugi-
nosa isolates was evaluated by pulsed-field gel electrophoresis (PFGE) using
restriction enzyme SpeI (GE Healthcare, Orsay, France) as described previously
(27). Analysis of PFGE patterns was performed by visual inspection of photo-
graphs of ethidium bromide-stained gels. The isolates were classified according
to the criteria described by Tenover et al. (36). The P. aeruginosa isolate 48-1997
(38), corresponding to the SPM-producing national clone, was included in PFGE
experiments for direct comparison of genotypes.
Genetic support of -lactamase-encoding genes. Plasmid extraction was per-
formed by the Kieser technique (13). E. coli NCTC50192, harboring four plas-
mids of 154, 66, 38, and 7 kb, was used as a size marker for plasmids. Transfor-
mation assays were performed by electroporation with plasmid extracts from the
identified positive isolates, and both E. coli TOP10 and P. aeruginosa PAO1 were
used as recipient strains. Selection was performed on agar plates supplemented
with 50 g/ml amoxicillin (amoxicilline) and 50 g/ml ticarcillin for E. coli and P.
aeruginosa, respectively. DNA-DNA hybridization of plasmid extracts was per-
formed with a Southern transfer onto a Hybond N nylon membrane (GE
Healthcare) as previously described. Labeling of the probe and signal detection
were carried out using an enhanced chemiluminescence nonradioactive labeling
and detection kit according to the manufacturer’s instructions (GE Healthcare).
The genetic localization of the -lactamase-encoding genes was also attempted
by using the endonuclease I-CeuI technique, as described previously (14).
Cloning experiments. Total DNA from P. aeruginosa 35 was HindIII re-
stricted, ligated into the corresponding site of plasmid pBK-CMV, and then
transformed in the E. coli TOP10 reference strain by electroporation as de-
scribed previously (25). Recombinant plasmids were selected on Trypticase soy
agar plates containing 1 g/ml imipenem and 30 g/ml kanamycin. The cloned
DNA fragment of recombinant plasmid p35 was sequenced on both strands.
RESULTS
Clinical data, susceptibility testing, and screening for AmpC
overproducers and ESBL producers. Forty-three out of the
154 P. aeruginosa isolates (28%) displayed ceftazidime resis-
tance. Table 1 summarizes the clinical data, antimicrobial sus-
ceptibility profiles, and molecular typing of those 43 isolates.
They were collected mainly from patients hospitalized in in-
tensive care units (25 isolates), the emergency room (10 iso-
lates), and the pediatric oncology unit (four isolates) (Table 1).
In summary, the retrospective analysis of medical records
showed that 24 patients (55.8%) had received adequate anti-
microbial therapy, while empirical treatment was not optimal
for 14 patients (32.5%). Additionally, the medical records of
five patients (11.6%) were not available. Among the 24 pa-
tients who had received adequate empirical treatment or for
whom antimicrobial therapy was correctly modified according
to the results of susceptibility testing, 10 were discharged after
7 or more days of antimicrobial therapy, nine died after 7 or
more days of treatment, and five died before 7 days of treat-
ment. Among the 14 patients who had received inadequate
empirical therapy, 10 died before results of antimicrobial sus-
ceptibility testing, whereas four patients were discharged. No-
tably, in quite a high number of cases, antibiotics such as
carbapenems and the last-resort antibiotic polymyxin B had
been used, although unsuccessfully for 20 out of 38 patients.
Corresponding clinical data are presented in Table 1.
The 43 ceftazidime-resistant isolates were also resistant to
ticarcillin, ticarcillin-clavulanic acid, cefpirome, and cefepime.
The highest susceptibility rates were obtained for colistin
(100%), followed by aztreonam (44.1%), piperacillin-tazobac-
tam (39.5%), piperacillin (34.8%), imipenem (18.6%), and
amikacin (18.6%). Only for piperacillin and piperacillin-
tazobactam were susceptibility rates obtained following the
breakpoints recommended by the European Committee on
Antimicrobial Susceptibility Testing (an isolate is deemed sus-
ceptible when the MIC is 16 mg/liter). Overproduction of
AmpC was identified to be likely the sole enzymatic mecha-
nism responsible for ceftazidime resistance in four isolates
(9.3%). Nine isolates were classified as ESBL producers.
Imipenem hydrolysis was observed for 30 isolates, all of
them resistant to imipenem. A high imipenem hydrolysis rate
was obtained for 28 isolates (average specific activity of 0.2
U  mg of protein1), and a lower but significant rate was
obtained for two isolates (average specific activity of 0.007
U  mg of protein1).
Identification of acquired -lactamase genes. The blaGES-1
(n  7) and blaCTX-M-2 (n  2) genes were identified in nine
isolates exhibiting an ESBL phenotype. In addition, the
blaGES-5 gene, which encodes an unusual ESBL with carbap-
enemase activity, was identified in two isolates which did not
display any ESBL phenotype but corresponded to the two
isolates for which weak carbapenem hydrolysis was detected.
The MBL-encoding genes blaSPM-1 and blaIMP-1 were identi-
fied in 27 isolates (62.8%) and one isolate (2.3%), respectively,
corresponding to those isolates for which a high imipenem
hydrolysis rate had been noted.
Clonal relationship. PFGE analysis performed with the 43
P. aeruginosa clinical isolates showed seven main genotypes.
The 27 SPM-1-producing isolates belonged to a single geno-
type, A (corresponding to the genotype of the Brazilian epi-
demic clone), which can be divided into two subtypes, A1 and
A2. GES-1-producing isolates belonged to either genotype B
(six isolates) or genotype C1 (one isolate). The two GES-5-
producing isolates belonged to genotype C2, which was closely
related to genotype C1 (two-band difference). The four AmpC
overproducers belonged to genotypes G (one isolate) and D
(three isolates), the latter being subclassified into two subtypes,
D1 (one isolate) and D2 (two isolates). Genotypes E and F
corresponded to the two CTX-M-2-producing isolates and the
single IMP-1-producing isolate, respectively (Table 1).
Genetics of -lactamase-encoding genes. PCR mapping and
sequencing revealed that the blaCTX-M-2 gene was preceded by
ISCR1 and followed by the qacE1 and sul1 tandem genes
(Fig. 1), as previously reported for Enterobacteriaceae (34).
ISCR elements are insertion sequences transposing in a par-
ticular way since they can mobilize adjacent sequences by roll-
ing-circle transposition (37). Analysis of the SPM-1-producing
strains showed that the blaSPM-1 gene was preceded by ISCR4
and followed by groEL and ISCR4 (Fig. 1) with a perfect
identity compared to the sequences previously reported from
blaSPM-1-producing P. aeruginosa isolates (27). Sequencing of
the 5 CS-3 CS amplicon obtained from isolate 42 showed that
the blaIMP-1 gene was located at the first position of a class 1
integron possessing the strong promoter configuration with
Pant and P2. Class 1 integrons are DNA structures that may
integrate or excise antibiotic resistance genes as a form of gene
cassettes (4). The blaIMP-1 gene was associated with the aadA1
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gene cassette encoding resistance to aminoglycosides in that
class 1 integron (Fig. 1).
Using the I-CeuI technique, no conclusive results regarding the
genetic location of blaCTX-M-2, blaSPM-1, and blaIMP-1 genes were
obtained. No plasmid was identified in the two blaCTX-M-2-posi-
tive isolates as well as in all blaSPM-1-positive isolates, whereas a
single plasmid of 100 kb was identified in the blaIMP-1-positive
isolate. Southern blot hybridization of plasmid DNA extracted
from blaCTX-M-2, blaSPM-1, and blaIMP-1-positive isolates using the
corresponding probes did not give a positive signal. In addition,
the transfer of these resistance determinants to both E. coli and P.
aeruginosa PAO1 recipient strains remained unsuccessful.
Detailed analysis of blaGES-positive isolates. In order to
detail the environment of the blaGES genes in P. aeruginosa
isolates, a cloning step was necessary. Cloning of HindIII-
digested total DNA from isolate 35 resulted in a blaGES-5-
positive recombinant plasmid containing an insert of approxi-
mately 10 kb. Sequencing of the insert revealed that the
blaGES-5 gene was located at the first position of a class 1
integron, followed by the aacA7 and aacA4 gene cassettes. The
59-base element (59-be) of the aacA4 gene cassette was inter-
rupted by a new insertion sequence element named ISPa29
belonging to the IS1111 family, members of which have been
shown to insert themselves into the recombination sites of gene
cassettes by site-specific recombination (32). ISPa29 was 1,534
bp long, possessed 12-bp-long imperfect subterminal inverted
repeats, and was not bracketed by any target site duplication as
commonly observed for IS1111 family members (Fig. 1) (32).
Its transposase shared 63% identity with that of IS1492 iden-
tified from Pseudomonas putida. The ISPa29 sequence has
been deposited on the IS Biotoul website (http://www-is
.biotoul.fr). This class 1 integron was bracketed by two copies
of IS26, located in opposite orientations as drawn in Fig. 1,
thus constituting a composite transposon structure, as already
found for another -lactamase gene (blaVEB-1)-positive inte-
gron, In53 (22).
Further PCR mapping used to target IS26 elements and the
gene cassettes for the blaGES-5- and blaGES-1-positive isolates
showed that they possessed the same class 1 integron structure.
That integron possessed the promoter Pant, whereas promoter
P2 was under an inactive form. As observed for the blaGES-1-
positive Klebsiella pneumoniae strain ORI-1 from French Gui-
ana (26), the blaGES-1 and blaGES-5 genes identified in our
isolates were purified as a form of gene cassette with a trun-
cated 59-be of 19 bp. Again, the I-CeuI technique did not allow
us to clarify whether those blaGES-like genes were chromo-
somally or plasmid located. In addition, plasmid analysis fol-
lowed by Southern blotting and hybridization with a blaGES-
specific probe performed with all blaGES-positive isolates failed
to identify any plasmid. In accordance with those latter nega-
tive results, repeated attempts to transfer the blaGES-1 and
blaGES-5 genes by transformation into E. coli or P. aeruginosa
recipient strains failed. Those results strongly suggested the
chromosomal location of the blaGES-like genes.
DISCUSSION
The rate of ceftazidime-resistant P. aeruginosa strains (28%)
isolated from blood cultures was quite high in this study. A
similarly high rate of resistance has been reported for many
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developing countries worldwide (42). Here we showed that this
high rate is mainly due to ESBL- and MBL-encoding genes,
together with the clonal spread of several specific clones. In-
terestingly, AmpC overproduction as a single enzymatic mech-
anism for ceftazidime resistance was rarely observed; it seemed
to be replaced by acquisition of -lactamases with an expanded
spectrum of activity. Worryingly, a very high proportion of
those isolates were also resistant to imipenem (82%) and
meropenem (95%), suggesting the presence of nonenzymatic
mechanisms of carbapenem resistance, such as porin loss
and/or overexpression of efflux pumps.
Our study showed that the blaGES-type ESBL genes were
identified in 13.9% of the ceftazidime-resistant P. aeruginosa
isolates and were divided into two distinct clones. Since
blaGES-1 and blaGES-5 genes were identified in the same P.
aeruginosa clone, it may correspond to a local evolution of this
clone. Considering that GES-5 possesses a wider spectrum of
hydrolysis than that of GES-1, it might be speculated that this
evolution could be due to a carbapenem-related selective pres-
sure. Notably, those blaGES-1 and blaGES-5 gene cassettes had a
truncated 59-be that was identical to that described in the
blaGES-1-positive K. pneumoniae ORI-I strain from French
Guiana (34). Since French Guiana and Brazil are neighboring
countries, those findings may suggest a spread of blaGES-re-
lated structures in that part of the world.
The present study underlines the idea that the current
spread of CTX-M enzymes may occur not only in the Entero-
bacteriaceae but also in P. aeruginosa. Interestingly, one recent
study carried out in the same Brazilian hospital found that
44.8% of K. pneumoniae clinical isolates were CTX-M-2 pro-
ducers (6). In addition, a CTX-M-2-producing P. aeruginosa
strain that was susceptible to ceftazidime was recently identi-
fied in this hospital (22). Such a spread of CTX-Ms may be
difficult to detect since many CTX-M variants confer a higher
degree of resistance to cefotaxime than to ceftazidime (34).
Therefore, since our selection criterion was based on ceftazi-
dime resistance, the rate of CTX-M production among P.
aeruginosa isolates identified here might be underestimated.
The genetic environments surrounding the blaCTX-M- and
blaGES-type -lactamase genes in P. aeruginosa were identical
to those identified in the Enterobacteriaceae, underlining their
common origin. It is likely that the location of the -lactamase
genes in P. aeruginosa results from their transfer from the
Enterobacteriaceae.
Overall, the production of SPM-1 carbapenemase was the
main source of resistance to ceftazidime, accounting for 62.8%
of the isolates. SPM-1-producing P. aeruginosa isolates are
widely disseminated in Brazil, with a single clone identified in
different cities (10). This clone has been also recently identified
in P. aeruginosa isolates recovered from Switzerland (9). We
showed here that this SPM-1-producing clone had been re-
sponsible for a large outbreak causing septicemia in 27 hospi-
talized patients, leading to the death of at least 15 of them.
This study underlines the possibility that a variety of -
lactamases with wide spectra of activity may circulate in P.
aeruginosa in Brazil, contributing to a multidrug resistance
phenotype. Lack of their identification and consequently lack
of isolation of carriers may lead to a further dissemination.
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